OBJECTIVES: Antidepressants can cause undesirable drug-drug interactions when taken concomitantly with certain medications. Elderly patients may be particularly vulnerable to antidepressant interactions due of slower metabolism and utilization of multiple pharmacotherapies. The objective of this study was to determine rates of potential drug-drug interactions involving antidepressants in a geriatric population and their impact on prescription adherence. METHODS: Data were from the MarketScan Medicare Database, a claims database from retirees with employersponsored Medicare supplemental insurance. Subjects were age 65 years, new antidepressant users, and had a depression diagnosis between 7/1/2001-12/31/2006. Potential drug-drug interactions involving at least one antidepressant and another drug with overlapping days supplied were identifi ed over the one year following antidepressant initiation using MicroMedex DRUG-REAX software. Multinomial logistic regression and bivariate statistics were used to evaluate the association between potential interactions and whether patients discontinued, refi lled or switched their fi rst antidepressant prescription. RESULTS: Among the 39,512 patients who met the inclusion criteria, 25.4% had potential contraindicated or major interactions, 36.1% had moderate interactions, and 38.5% had minor or no interactions. Compared to the moderate/minor/no interactions groups, the contraindicated/major group had a greater prevalence of medical comorbidities and higher comorbidity indices (p 0.001). Amitriptyline hydrochloride was involved in 19.1% of the potential contraindicated/ major interactions. Tramadol hydrochloride and oxycodone, opioid analgesics, were the most common medications with contraindicated/major interactions. Presence of contraindicated/major and moderate interactions was associated with an increase probability of switching to a different antidepressant of 23 and 11 percentage points, respectively (p .001) and decreased probability of discontinuing of 3.5 and 2.5 percentage points (p 0.001), after controlling for age, gender, pre-period mental disorders and medical comorbidities, antidepressant treatment type, and use of other psychotropic medications. CONCLUSIONS: Elderly antidepressant users frequently use medications with the potential for interactions with their antidepressant medication. There is a need for antidepressants with improved interaction profi les. Patients prescribed a regimen of atypical antipsychotic medications face many challenges. Adherence and persistence rates are typically low. We investigated determinants of adherence and persistence to second-generation antipsychotic medications (SGAs) for patients with schizophrenia and bipolar disorder, including fi nancial factors (patient cost-sharing and out-of-pocket burden) and formulary status. METHODS: A retrospective study of patients aged 18-64 years with at least one SGA claim, 24 months of continuous enrollment and employer-based coverage via large US fi rms in 2003-2006 (n 9714). The study initiation index date was defi ned as the fi rst SGA fi ll following a 12-month period without use of SGAs. Multivariate Cox proportional hazards models were estimated for persistence to SGAs (using a 30-, 60-and 90-day gap in therapy) and multivariate cross-section/time-series models were estimated for SGA adherence (PDC 80%). Explanatory variables included patient, plan, and provider characteristics, health status, cost-sharing (prescription drug and medical) and time. An empirical measure of SGA formulary status was developed. RESULTS: Over three quarters of patients (83%) discontinued SGA treatment and average persistence until a 90-day gap was 184 days. Higher prescription drug and offi ce visit patient cost-sharing amounts were associated with shorter time on SGAs, especially when cost-sharing exceeded $40 per fi ll or visit (95% confi dence interval hazard ratio for 90-day gap (1.01,1.15) prescription drug (1.00,1.24) offi ce visit) relative to costsharing of $. Higher prescription drug cost-sharing and patient total (drug and medical) out-of-pocket burden (measured in the previous 12 months) were associated with lower levels of adherence (both p 0.01). CONCLUSIONS: Even in a well-insured patient population, benefi t plan design factors can affect adherence and persistence to SGAs for patients with schizophrenia and bipolar disorder. Insurers and plan managers should take note of the prescription drug and medical plan design attributes that infl uence adherence to medications among this vulnerable patient group. were used to identify patients with schizophrenia who initiated treatment using a typical or atypical antipsychotic, a mood stabilizer or an antidepressant. Episodes were divided into three categories: restarting treatment after a break in drug therapy 15 days with the drug used in the previous episode; switching therapy with or without a break in treatment; and augmentation therapy. First observed episodes were excluded due to uncertainty concerning the patient's prior treatment history. A total of 21,872 episodes were included in ordinary least squares (OLS) regression models of post-treatment cost as a function of alternative defi nitions of compliance adjusting for age, gender, geographic region, drug use history, prior medical care use, schizophrenia diagnosis and co-morbid medical conditions. RESULTS: Adding a second medication within one year is the key factor in the relationship between compliance and one-year costs. One year of uninterrupted therapy on the initial drug without adding a second medication increased drug costs by $3314, while reducing medical costs by $3919 (p 0.0001 for both estimates) and total cost by $605 (p 0.05). One year of therapy on the initial drug augmented with a second medication increased drug costs ( $5062) and medical costs ( $3477) compared to non-compliance (p 0.0001 for both estimates). One year of uninterrupted therapy on a second drug after terminating the initial therapy was associated with the highest costs: $3,955 for drugs and $8,902 for medical services (p 0.0001 for all estimates). Analyses conducted separately by type of episode confi rmed these patterns of cost estimates. CONCLUSIONS: Compliance is associated with signifi cant reductions in medical costs only if the patient is maintained on their initial drug regimen. Changes in therapy are associated with higher medical costs. The objective of this study was too characterize geriatric antidepressant users' rate of claims documented treatment-related side-effects, and their impact on prescription-adherence and costs. METHODS: Data were from the MarketScan Medicare Database, a de-identifi ed health care database for retirees with employersponsored Medicare supplemental insurance. Subjects age 65 years who were new antidepressant users with a depression diagnosis were identifi ed between July 1, 2001-December 31, 2006. Twelve commonly reported antidepressant side-effects were identifi ed through ICD-9-CM diagnoses. Multinomial logistic regression was used to evaluate the effect of side-effects on adherence. RESULTS: A total of 39,512 treatment-naïve antidepressants users were selected and compared to 1,144,481 non-users. Antidepressant users were slighter older than non-users (76.5 vs. 75.6 years, p 0.001), more were female (63.2% vs. 52.5, p 0.001), and had higher prevalence of psychiatric, and non-psychiatric conditions. Approximately 5.5% (n 2214) of SSRI/ SNI users had diagnoses indicating side-effects within the fi rst 30-days of treatment. Approximately 18% of new antidepressant users switched antidepressants, 23% discontinued, and 59% refi lled after their fi rst prescription fi ll. The presence of a documented side-effect was associated with a 28.5% (4.7 percentage points) increase in the probability of switching and a 16.8% increase in the rate of discontinuation (3.7 percentage points) (p 0.01). The average cost of medical and pharmaceutical treatment for antidepressant side effects over the fi rst month of treatment was approximately $336 (SD $167). The cost of treating side-effects added $20.15 (1.8%) to the total health care costs of the all antidepressant users during their fi rst month after antidepressant initiation. CONCLUSIONS: Antidepressant therapy in the elderly is associated with a signifi cant level of side effects, which in turn is associated with lower adherence, and greater cost of depression care. There is a need for an antidepressant with improved tolerability profi le for the elderly to minimize non-adherence and economic burden to payers.
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PMH42 IMPACT OF ALTERNATIVE DEFINITIONS OF MEDICATION COMPLIANCE ON FIRST YEAR TREATMENT COST FOR PATIENTS WITH

